A phase 1 clinical trial at Washington University found a personalized DNA vaccine for glioblastoma is safe and elicits robust immune responses that may improve survival outcomes.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Personalized vaccine shows promise against aggressive brain cancer
4 In 100,000 Glioblastoma incidence
Phase 1 Trial phase
Nearly 5 Years Recurrence-Free Long-term survivor
None Serious Side effects
Nearly 5 Years survival without recurrence